In this randomized controlled trial, among patients with persistent chylomicronemia, it was found that plozasiran more ...

[Lp(a)], and apolipoprotein C-III (ApoC-III) were observed. Regarding safety, 94% of treatment related adverse events were considered mild or moderate.

Drugs from Ionis and Arrowhead Pharma that block apolipoprotein C-III (apoC-III) have shown their value in treating diseases associated with elevated triglyceride levels in two studies presented ...

The data also showed that olezarsen demonstrated robust and sustained reductions in TGs and serum apolipoprotein C-III (apoC-III) levels. It also reduced the incidence of acute pancreatitis (AP ...